#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=We noted a constant increase in the incidence of IE in Spain , principally because of a dramatic rise in the proportion of NIE concurrent with a decline in the percentage of CIE .
2-1	14-16	We	person	acc	ana	14-1
2-2	17-22	noted	_	_	_	_
2-3	23-24	a	abstract[3]	new[3]	coref	7-18[49_3]
2-4	25-33	constant	abstract[3]	new[3]	_	_
2-5	34-42	increase	abstract[3]	new[3]	_	_
2-6	43-45	in	abstract[3]	new[3]	_	_
2-7	46-49	the	abstract[3]|abstract[4]	new[3]|new[4]	coref	4-4[20_4]
2-8	50-59	incidence	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-9	60-62	of	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-10	63-65	IE	abstract[3]|abstract[4]|object[5]	new[3]|new[4]|new[5]	coref	7-9[0_5]
2-11	66-68	in	abstract[3]|abstract[4]|object[5]	new[3]|new[4]|new[5]	_	_
2-12	69-74	Spain	abstract[3]|abstract[4]|object[5]|place	new[3]|new[4]|new[5]|new	coref	7-27
2-13	75-76	,	_	_	_	_
2-14	77-88	principally	event[7]	new[7]	coref	21-1[183_7]
2-15	89-96	because	event[7]	new[7]	_	_
2-16	97-99	of	event[7]	new[7]	_	_
2-17	100-101	a	event[7]	new[7]	_	_
2-18	102-110	dramatic	event[7]	new[7]	_	_
2-19	111-115	rise	event[7]	new[7]	_	_
2-20	116-118	in	event[7]	new[7]	_	_
2-21	119-122	the	event[7]|quantity[8]	new[7]|new[8]	_	_
2-22	123-133	proportion	event[7]|quantity[8]	new[7]|new[8]	_	_
2-23	134-136	of	event[7]|quantity[8]	new[7]|new[8]	_	_
2-24	137-140	NIE	event[7]|quantity[8]|abstract[9]	new[7]|new[8]|new[9]	coref	3-1[0_9]
2-25	141-151	concurrent	event[7]|quantity[8]|abstract[9]	new[7]|new[8]|new[9]	_	_
2-26	152-156	with	_	_	_	_
2-27	157-158	a	event[10]	new[10]	coref	19-10[147_10]
2-28	159-166	decline	event[10]	new[10]	_	_
2-29	167-169	in	event[10]	new[10]	_	_
2-30	170-173	the	event[10]|quantity[11]	new[10]|new[11]	_	_
2-31	174-184	percentage	event[10]|quantity[11]	new[10]|new[11]	_	_
2-32	185-187	of	event[10]|quantity[11]	new[10]|new[11]	_	_
2-33	188-191	CIE	event[10]|quantity[11]|abstract	new[10]|new[11]|new	coref	3-6
2-34	192-193	.	_	_	_	_

#Text=NIE showed higher morbidity than CIE , as elderly patients were the most affected group .
3-1	194-197	NIE	abstract	giv	coref	5-27[34_0]
3-2	198-204	showed	_	_	_	_
3-3	205-211	higher	abstract[14]	new[14]	_	_
3-4	212-221	morbidity	abstract[14]	new[14]	_	_
3-5	222-226	than	abstract[14]	new[14]	_	_
3-6	227-230	CIE	abstract[14]|abstract	new[14]|giv	coref	4-6
3-7	231-232	,	_	_	_	_
3-8	233-235	as	_	_	_	_
3-9	236-243	elderly	person[16]	new[16]	coref	3-12[17_16]
3-10	244-252	patients	person[16]	new[16]	_	_
3-11	253-257	were	_	_	_	_
3-12	258-261	the	person[17]	giv[17]	coref	10-10[75_17]
3-13	262-266	most	person[17]	giv[17]	_	_
3-14	267-275	affected	person[17]	giv[17]	_	_
3-15	276-281	group	person[17]	giv[17]	_	_
3-16	282-283	.	_	_	_	_

#Text=The North reported the highest CIE incidence .
4-1	284-287	The	place[18]	new[18]	coref	25-15[219_18]
4-2	288-293	North	place[18]	new[18]	_	_
4-3	294-302	reported	_	_	_	_
4-4	303-306	the	abstract[20]	giv[20]	_	_
4-5	307-314	highest	abstract[20]	giv[20]	_	_
4-6	315-318	CIE	abstract|abstract[20]	giv|giv[20]	coref	5-30
4-7	319-328	incidence	abstract[20]	giv[20]	_	_
4-8	329-330	.	_	_	_	_

#Text=Cox regression analysis revealed that age , Charlson index , hemodialysis , shock , heart failure , and stroke were independent risk factors of mortality for both NIE and CIE .
5-1	331-334	Cox	person|abstract[23]	new|new[23]	_	_
5-2	335-345	regression	abstract|abstract[23]	new|new[23]	_	_
5-3	346-354	analysis	abstract[23]	new[23]	_	_
5-4	355-363	revealed	_	_	_	_
5-5	364-368	that	substance[24]	new[24]	appos	5-8[26_24]
5-6	369-372	age	substance[24]	new[24]	_	_
5-7	373-374	,	_	_	_	_
5-8	375-383	Charlson	person|abstract[26]	new|giv[26]	coref|coref	20-5[163_26]|20-5[163_26]
5-9	384-389	index	abstract[26]	giv[26]	_	_
5-10	390-391	,	abstract[26]	giv[26]	_	_
5-11	392-404	hemodialysis	abstract[26]	giv[26]	_	_
5-12	405-406	,	abstract[26]	giv[26]	_	_
5-13	407-412	shock	abstract[26]|event	giv[26]|new	coref	20-39
5-14	413-414	,	abstract[26]	giv[26]	_	_
5-15	415-420	heart	abstract[26]|object|event[29]	giv[26]|new|new[29]	coref|coref|coref|coref	20-41|20-41[178_29]|20-41|20-41[178_29]
5-16	421-428	failure	abstract[26]|event[29]	giv[26]|new[29]	_	_
5-17	429-430	,	abstract[26]	giv[26]	_	_
5-18	431-434	and	abstract[26]	giv[26]	_	_
5-19	435-441	stroke	abstract[26]|event	giv[26]|new	_	_
5-20	442-446	were	_	_	_	_
5-21	447-458	independent	abstract[32]	new[32]	_	_
5-22	459-463	risk	abstract|abstract[32]	new|new[32]	coref	23-42[204_0]
5-23	464-471	factors	abstract[32]	new[32]	_	_
5-24	472-474	of	abstract[32]	new[32]	_	_
5-25	475-484	mortality	abstract[32]|abstract[33]	new[32]|new[33]	coref	23-46[205_33]
5-26	485-488	for	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-27	489-493	both	abstract[32]|abstract[33]|abstract[34]	new[32]|new[33]|giv[34]	coref	9-5[0_34]
5-28	494-497	NIE	abstract[32]|abstract[33]|abstract[34]	new[32]|new[33]|giv[34]	_	_
5-29	498-501	and	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-30	502-505	CIE	abstract[32]|abstract[33]|abstract	new[32]|new[33]|giv	coref	6-21
5-31	506-507	.	_	_	_	_

#Text=In addition , the female sex , renal disease , and use of pacemakers or defibrillators were mortality-associated factors of CIE .
6-1	508-510	In	_	_	_	_
6-2	511-519	addition	_	_	_	_
6-3	520-521	,	_	_	_	_
6-4	522-525	the	abstract[36]	new[36]	_	_
6-5	526-532	female	abstract[36]	new[36]	_	_
6-6	533-536	sex	abstract[36]	new[36]	_	_
6-7	537-538	,	_	_	_	_
6-8	539-544	renal	abstract|abstract[38]	new|new[38]	coref|coref	15-16[115_38]|15-16[115_38]
6-9	545-552	disease	abstract[38]	new[38]	_	_
6-10	553-554	,	_	_	_	_
6-11	555-558	and	_	_	_	_
6-12	559-562	use	abstract[39]	new[39]	coref	6-18[42_39]
6-13	563-565	of	abstract[39]	new[39]	_	_
6-14	566-576	pacemakers	abstract[39]|object	new[39]|new	_	_
6-15	577-579	or	abstract[39]	new[39]	_	_
6-16	580-594	defibrillators	abstract[39]|object	new[39]|new	_	_
6-17	595-599	were	_	_	_	_
6-18	600-620	mortality-associated	abstract[42]	giv[42]	coref	20-2[161_42]
6-19	621-628	factors	abstract[42]	giv[42]	_	_
6-20	629-631	of	abstract[42]	giv[42]	_	_
6-21	632-635	CIE	abstract[42]|abstract	giv[42]|giv	_	_
6-22	636-637	.	_	_	_	_

#Text=Numerous studies have confirmed a rising trend of IE rates over time . Olmos et al. found a significant increase in the incidence of IE in Spain from 2003 to 2014 .
7-1	638-646	Numerous	event[44]	new[44]	coref	16-24[126_44]
7-2	647-654	studies	event[44]	new[44]	_	_
7-3	655-659	have	_	_	_	_
7-4	660-669	confirmed	_	_	_	_
7-5	670-671	a	abstract[45]	new[45]	coref	13-1[94_45]
7-6	672-678	rising	abstract[45]	new[45]	_	_
7-7	679-684	trend	abstract[45]	new[45]	_	_
7-8	685-687	of	abstract[45]	new[45]	_	_
7-9	688-690	IE	abstract[45]|object|abstract[47]	new[45]|giv|new[47]	coref|coref|coref|coref	7-25[51_0]|21-32[192_47]|7-25[51_0]|21-32[192_47]
7-10	691-696	rates	abstract[45]|abstract[47]	new[45]|new[47]	_	_
7-11	697-701	over	abstract[45]|abstract[47]	new[45]|new[47]	_	_
7-12	702-706	time	abstract[45]|abstract[47]	new[45]|new[47]	_	_
7-13	707-708	.	_	_	_	_
7-14	709-714	Olmos	person	new	_	_
7-15	715-717	et	_	_	_	_
7-16	718-721	al.	_	_	_	_
7-17	722-727	found	_	_	_	_
7-18	728-729	a	abstract[49]	giv[49]	coref	9-10[66_49]
7-19	730-741	significant	abstract[49]	giv[49]	_	_
7-20	742-750	increase	abstract[49]	giv[49]	_	_
7-21	751-753	in	abstract[49]	giv[49]	_	_
7-22	754-757	the	abstract[49]|abstract[50]	giv[49]|new[50]	_	_
7-23	758-767	incidence	abstract[49]|abstract[50]	giv[49]|new[50]	_	_
7-24	768-770	of	abstract[49]|abstract[50]	giv[49]|new[50]	_	_
7-25	771-773	IE	abstract[49]|abstract[50]|object[51]	giv[49]|new[50]|giv[51]	coref	8-11[0_51]
7-26	774-776	in	abstract[49]|abstract[50]|object[51]	giv[49]|new[50]|giv[51]	_	_
7-27	777-782	Spain	abstract[49]|abstract[50]|object[51]|place	giv[49]|new[50]|giv[51]|giv	coref	25-1[214_0]
7-28	783-787	from	_	_	_	_
7-29	788-792	2003	time	new	_	_
7-30	793-795	to	_	_	_	_
7-31	796-800	2014	time	new	_	_
7-32	801-802	.	_	_	_	_

#Text=Similarly , Bor et al. reported the rising number of IE episodes is due to Staphylococcus aureus infections associated with cardiac devices and implants .
8-1	803-812	Similarly	_	_	_	_
8-2	813-814	,	_	_	_	_
8-3	815-818	Bor	person	new	_	_
8-4	819-821	et	_	_	_	_
8-5	822-825	al.	_	_	_	_
8-6	826-834	reported	_	_	_	_
8-7	835-838	the	event[56]	new[56]	_	_
8-8	839-845	rising	event[56]	new[56]	_	_
8-9	846-852	number	event[56]	new[56]	_	_
8-10	853-855	of	event[56]	new[56]	_	_
8-11	856-858	IE	event[56]|object|abstract[58]	new[56]|giv|new[58]	coref|coref|coref|coref	10-7|14-28[110_58]|10-7|14-28[110_58]
8-12	859-867	episodes	event[56]|abstract[58]	new[56]|new[58]	_	_
8-13	868-870	is	_	_	_	_
8-14	871-874	due	_	_	_	_
8-15	875-877	to	_	_	_	_
8-16	878-892	Staphylococcus	object|abstract[61]	new|new[61]	coref|coref|coref|coref	19-41[156_61]|29-20|19-41[156_61]|29-20
8-17	893-899	aureus	object|abstract[61]	new|new[61]	_	_
8-18	900-910	infections	abstract[61]	new[61]	_	_
8-19	911-921	associated	_	_	_	_
8-20	922-926	with	_	_	_	_
8-21	927-934	cardiac	object[62]	new[62]	_	_
8-22	935-942	devices	object[62]	new[62]	_	_
8-23	943-946	and	_	_	_	_
8-24	947-955	implants	object	new	_	_
8-25	956-957	.	_	_	_	_

#Text=The growing incidence of NIE could be related to the increase in the prevalence of healthcare-associated interventional procedures in recent years ( e. g. , hemodialysis , catheterization , intravenous line placement , cardiac implantable electronic devices , prostheses ) .
9-1	958-961	The	abstract[64]	new[64]	_	_
9-2	962-969	growing	abstract[64]	new[64]	_	_
9-3	970-979	incidence	abstract[64]	new[64]	_	_
9-4	980-982	of	abstract[64]	new[64]	_	_
9-5	983-986	NIE	abstract[64]|abstract	new[64]|giv	coref	14-10
9-6	987-992	could	_	_	_	_
9-7	993-995	be	_	_	_	_
9-8	996-1003	related	_	_	_	_
9-9	1004-1006	to	_	_	_	_
9-10	1007-1010	the	abstract[66]	giv[66]	coref	13-11[96_66]
9-11	1011-1019	increase	abstract[66]	giv[66]	_	_
9-12	1020-1022	in	abstract[66]	giv[66]	_	_
9-13	1023-1026	the	abstract[66]|abstract[67]	giv[66]|new[67]	ana	10-3[0_67]
9-14	1027-1037	prevalence	abstract[66]|abstract[67]	giv[66]|new[67]	_	_
9-15	1038-1040	of	abstract[66]|abstract[67]	giv[66]|new[67]	_	_
9-16	1041-1062	healthcare-associated	abstract[66]|abstract[67]|abstract[68]	giv[66]|new[67]|new[68]	coref	12-24[90_68]
9-17	1063-1077	interventional	abstract[66]|abstract[67]|abstract[68]	giv[66]|new[67]|new[68]	_	_
9-18	1078-1088	procedures	abstract[66]|abstract[67]|abstract[68]	giv[66]|new[67]|new[68]	_	_
9-19	1089-1091	in	abstract[66]|abstract[67]|abstract[68]	giv[66]|new[67]|new[68]	_	_
9-20	1092-1098	recent	abstract[66]|abstract[67]|abstract[68]|time[69]	giv[66]|new[67]|new[68]|new[69]	coref	10-14[76_69]
9-21	1099-1104	years	abstract[66]|abstract[67]|abstract[68]|time[69]	giv[66]|new[67]|new[68]|new[69]	_	_
9-22	1105-1106	(	_	_	_	_
9-23	1107-1109	e.	_	_	_	_
9-24	1110-1112	g.	_	_	_	_
9-25	1113-1114	,	_	_	_	_
9-26	1115-1127	hemodialysis	_	_	_	_
9-27	1128-1129	,	_	_	_	_
9-28	1130-1145	catheterization	_	_	_	_
9-29	1146-1147	,	_	_	_	_
9-30	1148-1159	intravenous	_	_	_	_
9-31	1160-1164	line	object	new	_	_
9-32	1165-1174	placement	_	_	_	_
9-33	1175-1176	,	_	_	_	_
9-34	1177-1184	cardiac	person	new	_	_
9-35	1185-1196	implantable	abstract	new	_	_
9-36	1197-1207	electronic	_	_	_	_
9-37	1208-1215	devices	_	_	_	_
9-38	1216-1217	,	_	_	_	_
9-39	1218-1228	prostheses	_	_	_	_
9-40	1229-1230	)	_	_	_	_
9-41	1231-1232	.	_	_	_	_

#Text=Furthermore , this probably explains why IE rose in those patients older than 80 years .
10-1	1233-1244	Furthermore	_	_	_	_
10-2	1245-1246	,	_	_	_	_
10-3	1247-1251	this	abstract	giv	_	_
10-4	1252-1260	probably	_	_	_	_
10-5	1261-1269	explains	_	_	_	_
10-6	1270-1273	why	_	_	_	_
10-7	1274-1276	IE	object	giv	coref	11-16
10-8	1277-1281	rose	_	_	_	_
10-9	1282-1284	in	_	_	_	_
10-10	1285-1290	those	person[75]	giv[75]	coref	12-29[92_75]
10-11	1291-1299	patients	person[75]	giv[75]	_	_
10-12	1300-1305	older	person[75]	giv[75]	_	_
10-13	1306-1310	than	_	_	_	_
10-14	1311-1313	80	time[76]	giv[76]	coref	21-28[190_76]
10-15	1314-1319	years	time[76]	giv[76]	_	_
10-16	1320-1321	.	_	_	_	_

#Text=Another factor explaining the consistently increasing pattern might be the changes in the prevention of IE .
11-1	1322-1329	Another	abstract[77]	new[77]	coref	11-10[79_77]
11-2	1330-1336	factor	abstract[77]	new[77]	_	_
11-3	1337-1347	explaining	_	_	_	_
11-4	1348-1351	the	abstract[78]	new[78]	_	_
11-5	1352-1364	consistently	abstract[78]	new[78]	_	_
11-6	1365-1375	increasing	abstract[78]	new[78]	_	_
11-7	1376-1383	pattern	abstract[78]	new[78]	_	_
11-8	1384-1389	might	_	_	_	_
11-9	1390-1392	be	_	_	_	_
11-10	1393-1396	the	abstract[79]	giv[79]	coref	23-37[203_79]
11-11	1397-1404	changes	abstract[79]	giv[79]	_	_
11-12	1405-1407	in	abstract[79]	giv[79]	_	_
11-13	1408-1411	the	abstract[79]|abstract[80]	giv[79]|new[80]	_	_
11-14	1412-1422	prevention	abstract[79]|abstract[80]	giv[79]|new[80]	_	_
11-15	1423-1425	of	abstract[79]|abstract[80]	giv[79]|new[80]	_	_
11-16	1426-1428	IE	abstract[79]|abstract[80]|object	giv[79]|new[80]|giv	coref	13-15
11-17	1429-1430	.	_	_	_	_

#Text=The American Heart Association in 2007 revised and changed the consensus for antibiotic prophylaxis , recommending the withdrawal of routine antibiotic prophylaxis for dental procedures in low-risk and moderate-risk patients and most other invasive procedures in all patients .
12-1	1431-1434	The	person[82]	new[82]	_	_
12-2	1435-1443	American	person[82]	new[82]	_	_
12-3	1444-1449	Heart	person[82]	new[82]	_	_
12-4	1450-1461	Association	person[82]	new[82]	_	_
12-5	1462-1464	in	person[82]	new[82]	_	_
12-6	1465-1469	2007	person[82]|time	new[82]|new	_	_
12-7	1470-1477	revised	_	_	_	_
12-8	1478-1481	and	_	_	_	_
12-9	1482-1489	changed	_	_	_	_
12-10	1490-1493	the	abstract[84]	new[84]	coref	19-53[0_84]
12-11	1494-1503	consensus	abstract[84]	new[84]	_	_
12-12	1504-1507	for	abstract[84]	new[84]	_	_
12-13	1508-1518	antibiotic	abstract[84]|substance|abstract[86]	new[84]|new|new[86]	coref|coref|coref|coref	12-21|12-20[89_86]|12-21|12-20[89_86]
12-14	1519-1530	prophylaxis	abstract[84]|abstract[86]	new[84]|new[86]	_	_
12-15	1531-1532	,	_	_	_	_
12-16	1533-1545	recommending	_	_	_	_
12-17	1546-1549	the	event[87]	new[87]	_	_
12-18	1550-1560	withdrawal	event[87]	new[87]	_	_
12-19	1561-1563	of	event[87]	new[87]	_	_
12-20	1564-1571	routine	event[87]|abstract[89]	new[87]|giv[89]	_	_
12-21	1572-1582	antibiotic	event[87]|substance|abstract[89]	new[87]|giv|giv[89]	_	_
12-22	1583-1594	prophylaxis	event[87]|abstract[89]	new[87]|giv[89]	_	_
12-23	1595-1598	for	event[87]|abstract[89]	new[87]|giv[89]	_	_
12-24	1599-1605	dental	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	coref	15-10[113_90]
12-25	1606-1616	procedures	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-26	1617-1619	in	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-27	1620-1628	low-risk	event[87]|abstract[89]|abstract[90]|abstract	new[87]|giv[89]|giv[90]|new	_	_
12-28	1629-1632	and	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-29	1633-1646	moderate-risk	event[87]|abstract[89]|abstract[90]|person[92]	new[87]|giv[89]|giv[90]|giv[92]	coref	12-37[93_92]
12-30	1647-1655	patients	event[87]|abstract[89]|abstract[90]|person[92]	new[87]|giv[89]|giv[90]|giv[92]	_	_
12-31	1656-1659	and	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-32	1660-1664	most	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-33	1665-1670	other	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-34	1671-1679	invasive	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-35	1680-1690	procedures	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-36	1691-1693	in	event[87]|abstract[89]|abstract[90]	new[87]|giv[89]|giv[90]	_	_
12-37	1694-1697	all	event[87]|abstract[89]|abstract[90]|person[93]	new[87]|giv[89]|giv[90]|giv[93]	coref	15-20[116_93]
12-38	1698-1706	patients	event[87]|abstract[89]|abstract[90]|person[93]	new[87]|giv[89]|giv[90]|giv[93]	_	_
12-39	1707-1708	.	_	_	_	_

#Text=A similar trend occurred in the United Kingdom , where a substantial increase in IE cases was reported after the introduction of these guidelines in 2008 .
13-1	1709-1710	A	abstract[94]	giv[94]	coref	18-7[137_94]
13-2	1711-1718	similar	abstract[94]	giv[94]	_	_
13-3	1719-1724	trend	abstract[94]	giv[94]	_	_
13-4	1725-1733	occurred	_	_	_	_
13-5	1734-1736	in	_	_	_	_
13-6	1737-1740	the	place[95]	new[95]	_	_
13-7	1741-1747	United	place[95]	new[95]	_	_
13-8	1748-1755	Kingdom	place[95]	new[95]	_	_
13-9	1756-1757	,	_	_	_	_
13-10	1758-1763	where	_	_	_	_
13-11	1764-1765	a	abstract[96]	giv[96]	_	_
13-12	1766-1777	substantial	abstract[96]	giv[96]	_	_
13-13	1778-1786	increase	abstract[96]	giv[96]	_	_
13-14	1787-1789	in	abstract[96]	giv[96]	_	_
13-15	1790-1792	IE	abstract[96]|object|abstract[98]	giv[96]|giv|new[98]	coref|coref|coref|coref	14-6[104_0]|19-13[148_98]|14-6[104_0]|19-13[148_98]
13-16	1793-1798	cases	abstract[96]|abstract[98]	giv[96]|new[98]	_	_
13-17	1799-1802	was	_	_	_	_
13-18	1803-1811	reported	_	_	_	_
13-19	1812-1817	after	_	_	_	_
13-20	1818-1821	the	event[99]	new[99]	_	_
13-21	1822-1834	introduction	event[99]	new[99]	_	_
13-22	1835-1837	of	event[99]	new[99]	_	_
13-23	1838-1843	these	event[99]|abstract[100]	new[99]|new[100]	_	_
13-24	1844-1854	guidelines	event[99]|abstract[100]	new[99]|new[100]	_	_
13-25	1855-1857	in	_	_	_	_
13-26	1858-1862	2008	time	new	_	_
13-27	1863-1864	.	_	_	_	_

#Text=We identified 45.9 % of all IE to be NIE , which is moderately higher than previous reports , accounting for 10 % to 30 % of all IE episodes .
14-1	1865-1867	We	person	giv	ana	16-2
14-2	1868-1878	identified	_	_	_	_
14-3	1879-1883	45.9	quantity[103]	new[103]	_	_
14-4	1884-1885	%	quantity[103]	new[103]	_	_
14-5	1886-1888	of	quantity[103]	new[103]	_	_
14-6	1889-1892	all	quantity[103]|object[104]	new[103]|giv[104]	coref	14-29[0_104]
14-7	1893-1895	IE	quantity[103]|object[104]	new[103]|giv[104]	_	_
14-8	1896-1898	to	_	_	_	_
14-9	1899-1901	be	_	_	_	_
14-10	1902-1905	NIE	abstract	giv	coref	19-26
14-11	1906-1907	,	_	_	_	_
14-12	1908-1913	which	_	_	_	_
14-13	1914-1916	is	_	_	_	_
14-14	1917-1927	moderately	_	_	_	_
14-15	1928-1934	higher	_	_	_	_
14-16	1935-1939	than	_	_	_	_
14-17	1940-1948	previous	abstract[106]	new[106]	_	_
14-18	1949-1956	reports	abstract[106]	new[106]	_	_
14-19	1957-1958	,	_	_	_	_
14-20	1959-1969	accounting	_	_	_	_
14-21	1970-1973	for	_	_	_	_
14-22	1974-1976	10	quantity[107]	new[107]	_	_
14-23	1977-1978	%	quantity[107]	new[107]	_	_
14-24	1979-1981	to	_	_	_	_
14-25	1982-1984	30	quantity[108]	new[108]	_	_
14-26	1985-1986	%	quantity[108]	new[108]	_	_
14-27	1987-1989	of	quantity[108]	new[108]	_	_
14-28	1990-1993	all	quantity[108]|abstract[110]	new[108]|giv[110]	_	_
14-29	1994-1996	IE	quantity[108]|object|abstract[110]	new[108]|giv|giv[110]	coref	18-22
14-30	1997-2005	episodes	quantity[108]|abstract[110]	new[108]|giv[110]	_	_
14-31	2006-2007	.	_	_	_	_

#Text=This finding might be related to the increment of invasive procedures , major incidence of degenerative valve disease in elderly patients , and longer intensive care unit and hospital stays .
15-1	2008-2012	This	abstract[111]	new[111]	_	_
15-2	2013-2020	finding	abstract[111]	new[111]	_	_
15-3	2021-2026	might	_	_	_	_
15-4	2027-2029	be	_	_	_	_
15-5	2030-2037	related	_	_	_	_
15-6	2038-2040	to	_	_	_	_
15-7	2041-2044	the	abstract[112]	new[112]	coref	19-28[154_112]
15-8	2045-2054	increment	abstract[112]	new[112]	_	_
15-9	2055-2057	of	abstract[112]	new[112]	_	_
15-10	2058-2066	invasive	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
15-11	2067-2077	procedures	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
15-12	2078-2079	,	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
15-13	2080-2085	major	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
15-14	2086-2095	incidence	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
15-15	2096-2098	of	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
15-16	2099-2111	degenerative	abstract[112]|abstract[113]|abstract[115]	new[112]|giv[113]|giv[115]	coref	20-21[170_115]
15-17	2112-2117	valve	abstract[112]|abstract[113]|object|abstract[115]	new[112]|giv[113]|new|giv[115]	_	_
15-18	2118-2125	disease	abstract[112]|abstract[113]|abstract[115]	new[112]|giv[113]|giv[115]	_	_
15-19	2126-2128	in	abstract[112]|abstract[113]|abstract[115]	new[112]|giv[113]|giv[115]	_	_
15-20	2129-2136	elderly	abstract[112]|abstract[113]|abstract[115]|person[116]	new[112]|giv[113]|giv[115]|giv[116]	coref	16-8[0_116]
15-21	2137-2145	patients	abstract[112]|abstract[113]|abstract[115]|person[116]	new[112]|giv[113]|giv[115]|giv[116]	_	_
15-22	2146-2147	,	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
15-23	2148-2151	and	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
15-24	2152-2158	longer	abstract[112]|abstract[113]|object[118]	new[112]|giv[113]|new[118]	_	_
15-25	2159-2168	intensive	abstract[112]|abstract[113]|object[118]	new[112]|giv[113]|new[118]	_	_
15-26	2169-2173	care	abstract[112]|abstract[113]|abstract|object[118]	new[112]|giv[113]|new|new[118]	_	_
15-27	2174-2178	unit	abstract[112]|abstract[113]|object[118]	new[112]|giv[113]|new[118]	_	_
15-28	2179-2182	and	_	_	_	_
15-29	2183-2191	hospital	place	new	_	_
15-30	2192-2197	stays	_	_	_	_
15-31	2198-2199	.	_	_	_	_

#Text=In our study , 24.5 % of patients underwent cardiac surgery during admission , which is similar to what has been reported in population-based studies from Italy and the United States .
16-1	2200-2202	In	_	_	_	_
16-2	2203-2206	our	person|event[121]	giv|new[121]	coref|ana|coref|ana	17-19[0_121]|19-19|17-19[0_121]|19-19
16-3	2207-2212	study	event[121]	new[121]	_	_
16-4	2213-2214	,	_	_	_	_
16-5	2215-2219	24.5	quantity[122]	new[122]	_	_
16-6	2220-2221	%	quantity[122]	new[122]	_	_
16-7	2222-2224	of	quantity[122]	new[122]	_	_
16-8	2225-2233	patients	quantity[122]|person	new[122]|giv	coref	18-20[141_0]
16-9	2234-2243	underwent	_	_	_	_
16-10	2244-2251	cardiac	event[124]	new[124]	_	_
16-11	2252-2259	surgery	event[124]	new[124]	_	_
16-12	2260-2266	during	_	_	_	_
16-13	2267-2276	admission	event	new	_	_
16-14	2277-2278	,	_	_	_	_
16-15	2279-2284	which	_	_	_	_
16-16	2285-2287	is	_	_	_	_
16-17	2288-2295	similar	_	_	_	_
16-18	2296-2298	to	_	_	_	_
16-19	2299-2303	what	_	_	_	_
16-20	2304-2307	has	_	_	_	_
16-21	2308-2312	been	_	_	_	_
16-22	2313-2321	reported	_	_	_	_
16-23	2322-2324	in	_	_	_	_
16-24	2325-2341	population-based	event[126]	giv[126]	_	_
16-25	2342-2349	studies	event[126]	giv[126]	_	_
16-26	2350-2354	from	event[126]	giv[126]	_	_
16-27	2355-2360	Italy	event[126]|place	giv[126]|new	_	_
16-28	2361-2364	and	event[126]	giv[126]	_	_
16-29	2365-2368	the	event[126]|place[128]	giv[126]|new[128]	coref	18-15[140_128]
16-30	2369-2375	United	event[126]|place[128]	giv[126]|new[128]	_	_
16-31	2376-2382	States	event[126]|place[128]	giv[126]|new[128]	_	_
16-32	2383-2384	.	_	_	_	_

#Text=In terms of gender , a major predominance of men was observed in comparison with women throughout the study period .
17-1	2385-2387	In	_	_	_	_
17-2	2388-2393	terms	_	_	_	_
17-3	2394-2396	of	_	_	_	_
17-4	2397-2403	gender	abstract	new	_	_
17-5	2404-2405	,	_	_	_	_
17-6	2406-2407	a	abstract[130]	new[130]	_	_
17-7	2408-2413	major	abstract[130]	new[130]	_	_
17-8	2414-2426	predominance	abstract[130]	new[130]	_	_
17-9	2427-2429	of	abstract[130]	new[130]	_	_
17-10	2430-2433	men	abstract[130]|person	new[130]|new	_	_
17-11	2434-2437	was	_	_	_	_
17-12	2438-2446	observed	_	_	_	_
17-13	2447-2449	in	_	_	_	_
17-14	2450-2460	comparison	abstract[132]	new[132]	_	_
17-15	2461-2465	with	abstract[132]	new[132]	_	_
17-16	2466-2471	women	abstract[132]|person[133]	new[132]|new[133]	ana	18-11[0_133]
17-17	2472-2482	throughout	abstract[132]|person[133]	new[132]|new[133]	_	_
17-18	2483-2486	the	abstract[132]|person[133]|abstract[135]	new[132]|new[133]|new[135]	coref	18-30[144_135]
17-19	2487-2492	study	abstract[132]|person[133]|event|abstract[135]	new[132]|new[133]|giv|new[135]	coref	18-31
17-20	2493-2499	period	abstract[132]|person[133]|abstract[135]	new[132]|new[133]|new[135]	_	_
17-21	2500-2501	.	_	_	_	_

#Text=Likewise , Toyoda et al. found a similar trend in their investigation conducted in the United States in which patients with IE were more likely to be male throughout the study period .
18-1	2502-2510	Likewise	_	_	_	_
18-2	2511-2512	,	_	_	_	_
18-3	2513-2519	Toyoda	person	new	coref	19-4
18-4	2520-2522	et	_	_	_	_
18-5	2523-2526	al.	_	_	_	_
18-6	2527-2532	found	_	_	_	_
18-7	2533-2534	a	abstract[137]	giv[137]	_	_
18-8	2535-2542	similar	abstract[137]	giv[137]	_	_
18-9	2543-2548	trend	abstract[137]	giv[137]	_	_
18-10	2549-2551	in	abstract[137]	giv[137]	_	_
18-11	2552-2557	their	abstract[137]|person|event[139]	giv[137]|giv|new[139]	_	_
18-12	2558-2571	investigation	abstract[137]|event[139]	giv[137]|new[139]	_	_
18-13	2572-2581	conducted	_	_	_	_
18-14	2582-2584	in	_	_	_	_
18-15	2585-2588	the	place[140]	giv[140]	_	_
18-16	2589-2595	United	place[140]	giv[140]	_	_
18-17	2596-2602	States	place[140]	giv[140]	_	_
18-18	2603-2605	in	_	_	_	_
18-19	2606-2611	which	_	_	_	_
18-20	2612-2620	patients	person[141]	giv[141]	coref	20-51[181_141]
18-21	2621-2625	with	person[141]	giv[141]	_	_
18-22	2626-2628	IE	person[141]|object	giv[141]|giv	coref	22-16
18-23	2629-2633	were	_	_	_	_
18-24	2634-2638	more	_	_	_	_
18-25	2639-2645	likely	_	_	_	_
18-26	2646-2648	to	_	_	_	_
18-27	2649-2651	be	_	_	_	_
18-28	2652-2656	male	_	_	_	_
18-29	2657-2667	throughout	_	_	_	_
18-30	2668-2671	the	time[144]	giv[144]	_	_
18-31	2672-2677	study	event|time[144]	giv|giv[144]	_	_
18-32	2678-2684	period	time[144]	giv[144]	_	_
18-33	2685-2686	.	_	_	_	_

#Text=In contrast with Toyoda et al. , who described a decline in the cases of nosocomial endocarditis , our findings highlight the paramount importance of NIE , the incidence of which steeply rose despite all the coordinated efforts to reduce hospital-acquired infections through mandatory continuous reporting , regulated interventions , or evidence-based consensus recommendations .
19-1	2687-2689	In	_	_	_	_
19-2	2690-2698	contrast	abstract[145]	new[145]	_	_
19-3	2699-2703	with	abstract[145]	new[145]	_	_
19-4	2704-2710	Toyoda	abstract[145]|person	new[145]|giv	coref	24-23
19-5	2711-2713	et	abstract[145]	new[145]	_	_
19-6	2714-2717	al.	abstract[145]	new[145]	_	_
19-7	2718-2719	,	_	_	_	_
19-8	2720-2723	who	_	_	_	_
19-9	2724-2733	described	_	_	_	_
19-10	2734-2735	a	event[147]	giv[147]	_	_
19-11	2736-2743	decline	event[147]	giv[147]	_	_
19-12	2744-2746	in	event[147]	giv[147]	_	_
19-13	2747-2750	the	event[147]|abstract[148]	giv[147]|giv[148]	_	_
19-14	2751-2756	cases	event[147]|abstract[148]	giv[147]|giv[148]	_	_
19-15	2757-2759	of	event[147]|abstract[148]	giv[147]|giv[148]	_	_
19-16	2760-2770	nosocomial	event[147]|abstract[148]|object[149]	giv[147]|giv[148]|new[149]	_	_
19-17	2771-2783	endocarditis	event[147]|abstract[148]|object[149]	giv[147]|giv[148]|new[149]	_	_
19-18	2784-2785	,	_	_	_	_
19-19	2786-2789	our	person|abstract[151]	giv|new[151]	coref|ana|coref|ana	24-27[213_151]|28-4|24-27[213_151]|28-4
19-20	2790-2798	findings	abstract[151]	new[151]	_	_
19-21	2799-2808	highlight	_	_	_	_
19-22	2809-2812	the	abstract[152]	new[152]	_	_
19-23	2813-2822	paramount	abstract[152]	new[152]	_	_
19-24	2823-2833	importance	abstract[152]	new[152]	_	_
19-25	2834-2836	of	abstract[152]	new[152]	_	_
19-26	2837-2840	NIE	abstract[152]|abstract	new[152]|giv	coref	20-53
19-27	2841-2842	,	_	_	_	_
19-28	2843-2846	the	abstract[154]	giv[154]	coref	26-1[235_154]
19-29	2847-2856	incidence	abstract[154]	giv[154]	_	_
19-30	2857-2859	of	_	_	_	_
19-31	2860-2865	which	_	_	_	_
19-32	2866-2873	steeply	_	_	_	_
19-33	2874-2878	rose	_	_	_	_
19-34	2879-2886	despite	_	_	_	_
19-35	2887-2890	all	event[155]	new[155]	_	_
19-36	2891-2894	the	event[155]	new[155]	_	_
19-37	2895-2906	coordinated	event[155]	new[155]	_	_
19-38	2907-2914	efforts	event[155]	new[155]	_	_
19-39	2915-2917	to	_	_	_	_
19-40	2918-2924	reduce	_	_	_	_
19-41	2925-2942	hospital-acquired	abstract[156]	giv[156]	coref	30-3[264_156]
19-42	2943-2953	infections	abstract[156]	giv[156]	_	_
19-43	2954-2961	through	abstract[156]	giv[156]	_	_
19-44	2962-2971	mandatory	abstract[156]|abstract[157]	giv[156]|new[157]	_	_
19-45	2972-2982	continuous	abstract[156]|abstract[157]	giv[156]|new[157]	_	_
19-46	2983-2992	reporting	abstract[156]|abstract[157]	giv[156]|new[157]	_	_
19-47	2993-2994	,	abstract[156]	giv[156]	_	_
19-48	2995-3004	regulated	abstract[156]|abstract[158]	giv[156]|new[158]	_	_
19-49	3005-3018	interventions	abstract[156]|abstract[158]	giv[156]|new[158]	_	_
19-50	3019-3020	,	abstract[156]	giv[156]	_	_
19-51	3021-3023	or	abstract[156]	giv[156]	_	_
19-52	3024-3038	evidence-based	abstract[156]|abstract[160]	giv[156]|new[160]	_	_
19-53	3039-3048	consensus	abstract[156]|abstract|abstract[160]	giv[156]|giv|new[160]	_	_
19-54	3049-3064	recommendations	abstract[156]|abstract[160]	giv[156]|new[160]	_	_
19-55	3065-3066	.	_	_	_	_

#Text=Concerning predisposing factors , a higher Charlson index ( reflecting more comorbidities such as diabetes mellitus , hemodialysis , coronary artery disease , peripheral artery disease , cancer , as well as major complications ranging from sepsis , shock , heart failure , and cerebrovascular disease ) were present in patients with NIE .
20-1	3067-3077	Concerning	_	_	_	_
20-2	3078-3090	predisposing	abstract[161]	giv[161]	_	_
20-3	3091-3098	factors	abstract[161]	giv[161]	_	_
20-4	3099-3100	,	abstract[161]	giv[161]	_	_
20-5	3101-3102	a	abstract[161]|abstract[163]	giv[161]|giv[163]	coref	20-18[0_163]
20-6	3103-3109	higher	abstract[161]|abstract[163]	giv[161]|giv[163]	_	_
20-7	3110-3118	Charlson	abstract[161]|person|abstract[163]	giv[161]|new|giv[163]	_	_
20-8	3119-3124	index	abstract[161]|abstract[163]	giv[161]|giv[163]	_	_
20-9	3125-3126	(	_	_	_	_
20-10	3127-3137	reflecting	_	_	_	_
20-11	3138-3142	more	abstract[164]	new[164]	_	_
20-12	3143-3156	comorbidities	abstract[164]	new[164]	_	_
20-13	3157-3161	such	abstract[164]	new[164]	_	_
20-14	3162-3164	as	abstract[164]	new[164]	_	_
20-15	3165-3173	diabetes	abstract[164]|abstract|abstract[166]	new[164]|new|new[166]	_	_
20-16	3174-3182	mellitus	abstract[164]|abstract[166]	new[164]|new[166]	_	_
20-17	3183-3184	,	abstract[164]	new[164]	_	_
20-18	3185-3197	hemodialysis	abstract[164]|abstract	new[164]|giv	_	_
20-19	3198-3199	,	abstract[164]	new[164]	_	_
20-20	3200-3208	coronary	abstract[164]|person	new[164]|new	_	_
20-21	3209-3215	artery	abstract[164]|object|abstract[170]	new[164]|new|giv[170]	coref|coref|coref|coref	20-25|20-24[172_170]|20-25|20-24[172_170]
20-22	3216-3223	disease	abstract[164]|abstract[170]	new[164]|giv[170]	_	_
20-23	3224-3225	,	abstract[164]	new[164]	_	_
20-24	3226-3236	peripheral	abstract[164]|abstract[172]	new[164]|giv[172]	coref	20-45[180_172]
20-25	3237-3243	artery	abstract[164]|object|abstract[172]	new[164]|giv|giv[172]	_	_
20-26	3244-3251	disease	abstract[164]|abstract[172]	new[164]|giv[172]	_	_
20-27	3252-3253	,	abstract[164]	new[164]	_	_
20-28	3254-3260	cancer	abstract[164]|abstract	new[164]|new	_	_
20-29	3261-3262	,	abstract[164]	new[164]	_	_
20-30	3263-3265	as	abstract[164]	new[164]	_	_
20-31	3266-3270	well	abstract[164]	new[164]	_	_
20-32	3271-3273	as	abstract[164]	new[164]	_	_
20-33	3274-3279	major	abstract[164]|abstract[174]	new[164]|new[174]	coref	23-24[201_174]
20-34	3280-3293	complications	abstract[164]|abstract[174]	new[164]|new[174]	_	_
20-35	3294-3301	ranging	_	_	_	_
20-36	3302-3306	from	_	_	_	_
20-37	3307-3313	sepsis	abstract	new	_	_
20-38	3314-3315	,	_	_	_	_
20-39	3316-3321	shock	event	giv	_	_
20-40	3322-3323	,	_	_	_	_
20-41	3324-3329	heart	object|abstract[178]	giv|giv[178]	_	_
20-42	3330-3337	failure	abstract[178]	giv[178]	_	_
20-43	3338-3339	,	_	_	_	_
20-44	3340-3343	and	_	_	_	_
20-45	3344-3359	cerebrovascular	abstract|abstract[180]	new|giv[180]	_	_
20-46	3360-3367	disease	abstract[180]	giv[180]	_	_
20-47	3368-3369	)	_	_	_	_
20-48	3370-3374	were	_	_	_	_
20-49	3375-3382	present	_	_	_	_
20-50	3383-3385	in	_	_	_	_
20-51	3386-3394	patients	person[181]	giv[181]	_	_
20-52	3395-3399	with	person[181]	giv[181]	_	_
20-53	3400-3403	NIE	person[181]|abstract	giv[181]|giv	coref	21-21
20-54	3404-3405	.	_	_	_	_

#Text=This rise in underlying diseases might be related to the aging of the population and explains why those adults with NIE , especially those older than age 80 years , depicted the lowest survival rates .
21-1	3406-3410	This	event[183]	giv[183]	_	_
21-2	3411-3415	rise	event[183]	giv[183]	_	_
21-3	3416-3418	in	event[183]	giv[183]	_	_
21-4	3419-3429	underlying	event[183]|abstract[184]	giv[183]|new[184]	_	_
21-5	3430-3438	diseases	event[183]|abstract[184]	giv[183]|new[184]	_	_
21-6	3439-3444	might	_	_	_	_
21-7	3445-3447	be	_	_	_	_
21-8	3448-3455	related	_	_	_	_
21-9	3456-3458	to	_	_	_	_
21-10	3459-3462	the	abstract[185]	new[185]	_	_
21-11	3463-3468	aging	abstract[185]	new[185]	_	_
21-12	3469-3471	of	abstract[185]	new[185]	_	_
21-13	3472-3475	the	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-14	3476-3486	population	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-15	3487-3490	and	_	_	_	_
21-16	3491-3499	explains	_	_	_	_
21-17	3500-3503	why	_	_	_	_
21-18	3504-3509	those	person[187]	new[187]	_	_
21-19	3510-3516	adults	person[187]	new[187]	_	_
21-20	3517-3521	with	person[187]	new[187]	_	_
21-21	3522-3525	NIE	person[187]|abstract	new[187]|giv	_	_
21-22	3526-3527	,	_	_	_	_
21-23	3528-3538	especially	_	_	_	_
21-24	3539-3544	those	_	_	_	_
21-25	3545-3550	older	_	_	_	_
21-26	3551-3555	than	_	_	_	_
21-27	3556-3559	age	abstract	new	_	_
21-28	3560-3562	80	time[190]	giv[190]	_	_
21-29	3563-3568	years	time[190]	giv[190]	_	_
21-30	3569-3570	,	_	_	_	_
21-31	3571-3579	depicted	_	_	_	_
21-32	3580-3583	the	abstract[192]	giv[192]	coref	23-21[200_192]
21-33	3584-3590	lowest	abstract[192]	giv[192]	_	_
21-34	3591-3599	survival	event|abstract[192]	new|giv[192]	_	_
21-35	3600-3605	rates	abstract[192]	giv[192]	_	_
21-36	3606-3607	.	_	_	_	_

#Text=Regarding the microbiological profile , Gram-positive pathogens are still the most frequent microorganisms associated with IE , as previously reported in other series .
22-1	3608-3617	Regarding	_	_	_	_
22-2	3618-3621	the	abstract[193]	new[193]	_	_
22-3	3622-3637	microbiological	abstract[193]	new[193]	_	_
22-4	3638-3645	profile	abstract[193]	new[193]	_	_
22-5	3646-3647	,	_	_	_	_
22-6	3648-3661	Gram-positive	abstract[194]	new[194]	coref	22-9[195_194]
22-7	3662-3671	pathogens	abstract[194]	new[194]	_	_
22-8	3672-3675	are	_	_	_	_
22-9	3676-3681	still	abstract[195]	giv[195]	coref	23-1[198_195]
22-10	3682-3685	the	abstract[195]	giv[195]	_	_
22-11	3686-3690	most	abstract[195]	giv[195]	_	_
22-12	3691-3699	frequent	abstract[195]	giv[195]	_	_
22-13	3700-3714	microorganisms	abstract[195]	giv[195]	_	_
22-14	3715-3725	associated	_	_	_	_
22-15	3726-3730	with	_	_	_	_
22-16	3731-3733	IE	object	giv	coref	23-49[206_0]
22-17	3734-3735	,	_	_	_	_
22-18	3736-3738	as	_	_	_	_
22-19	3739-3749	previously	_	_	_	_
22-20	3750-3758	reported	_	_	_	_
22-21	3759-3761	in	_	_	_	_
22-22	3762-3767	other	abstract[197]	new[197]	_	_
22-23	3768-3774	series	abstract[197]	new[197]	_	_
22-24	3775-3776	.	_	_	_	_

#Text=These microorganisms often have a healthcare-associated origin , widely recognized as virulent and resistant organisms , and are related to high rates of complications and high mortality rates . Selton-Suty et al. demonstrated Staphylococcus aureus as the only factor associated with a higher risk of in-hospital mortality in healthcare-associated IE .
23-1	3777-3782	These	abstract[198]	giv[198]	coref	24-15[211_198]
23-2	3783-3797	microorganisms	abstract[198]	giv[198]	_	_
23-3	3798-3803	often	_	_	_	_
23-4	3804-3808	have	_	_	_	_
23-5	3809-3810	a	abstract[199]	new[199]	_	_
23-6	3811-3832	healthcare-associated	abstract[199]	new[199]	_	_
23-7	3833-3839	origin	abstract[199]	new[199]	_	_
23-8	3840-3841	,	_	_	_	_
23-9	3842-3848	widely	_	_	_	_
23-10	3849-3859	recognized	_	_	_	_
23-11	3860-3862	as	_	_	_	_
23-12	3863-3871	virulent	_	_	_	_
23-13	3872-3875	and	_	_	_	_
23-14	3876-3885	resistant	_	_	_	_
23-15	3886-3895	organisms	_	_	_	_
23-16	3896-3897	,	_	_	_	_
23-17	3898-3901	and	_	_	_	_
23-18	3902-3905	are	_	_	_	_
23-19	3906-3913	related	_	_	_	_
23-20	3914-3916	to	_	_	_	_
23-21	3917-3921	high	abstract[200]	giv[200]	coref	28-18[255_200]
23-22	3922-3927	rates	abstract[200]	giv[200]	_	_
23-23	3928-3930	of	abstract[200]	giv[200]	_	_
23-24	3931-3944	complications	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
23-25	3945-3948	and	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
23-26	3949-3953	high	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
23-27	3954-3963	mortality	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
23-28	3964-3969	rates	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
23-29	3970-3971	.	_	_	_	_
23-30	3972-3983	Selton-Suty	person	new	_	_
23-31	3984-3986	et	_	_	_	_
23-32	3987-3990	al.	_	_	_	_
23-33	3991-4003	demonstrated	_	_	_	_
23-34	4004-4018	Staphylococcus	_	_	_	_
23-35	4019-4025	aureus	_	_	_	_
23-36	4026-4028	as	_	_	_	_
23-37	4029-4032	the	abstract[203]	giv[203]	_	_
23-38	4033-4037	only	abstract[203]	giv[203]	_	_
23-39	4038-4044	factor	abstract[203]	giv[203]	_	_
23-40	4045-4055	associated	_	_	_	_
23-41	4056-4060	with	_	_	_	_
23-42	4061-4062	a	abstract[204]	giv[204]	_	_
23-43	4063-4069	higher	abstract[204]	giv[204]	_	_
23-44	4070-4074	risk	abstract[204]	giv[204]	_	_
23-45	4075-4077	of	abstract[204]	giv[204]	_	_
23-46	4078-4089	in-hospital	abstract[204]|abstract[205]	giv[204]|giv[205]	coref	24-11[0_205]
23-47	4090-4099	mortality	abstract[204]|abstract[205]	giv[204]|giv[205]	_	_
23-48	4100-4102	in	abstract[204]|abstract[205]	giv[204]|giv[205]	_	_
23-49	4103-4124	healthcare-associated	abstract[204]|abstract[205]|object[206]	giv[204]|giv[205]|giv[206]	coref	26-3[0_206]
23-50	4125-4127	IE	abstract[204]|abstract[205]|object[206]	giv[204]|giv[205]|giv[206]	_	_
23-51	4128-4129	.	_	_	_	_

#Text=Compared with fungi , anaerobic , and streptococcal infection , mortality was higher for Gram-positive and Gram-negative pathogens , which differs from Toyoda et al. ’ s findings .
24-1	4130-4138	Compared	_	_	_	_
24-2	4139-4143	with	_	_	_	_
24-3	4144-4149	fungi	plant	new	_	_
24-4	4150-4151	,	_	_	_	_
24-5	4152-4161	anaerobic	substance	new	_	_
24-6	4162-4163	,	_	_	_	_
24-7	4164-4167	and	_	_	_	_
24-8	4168-4181	streptococcal	abstract[209]	new[209]	_	_
24-9	4182-4191	infection	abstract[209]	new[209]	_	_
24-10	4192-4193	,	_	_	_	_
24-11	4194-4203	mortality	abstract	giv	_	_
24-12	4204-4207	was	_	_	_	_
24-13	4208-4214	higher	_	_	_	_
24-14	4215-4218	for	_	_	_	_
24-15	4219-4232	Gram-positive	abstract[211]	giv[211]	_	_
24-16	4233-4236	and	abstract[211]	giv[211]	_	_
24-17	4237-4250	Gram-negative	abstract[211]	giv[211]	_	_
24-18	4251-4260	pathogens	abstract[211]	giv[211]	_	_
24-19	4261-4262	,	_	_	_	_
24-20	4263-4268	which	_	_	_	_
24-21	4269-4276	differs	_	_	_	_
24-22	4277-4281	from	_	_	_	_
24-23	4282-4288	Toyoda	person	giv	_	_
24-24	4289-4291	et	_	_	_	_
24-25	4292-4295	al.	_	_	_	_
24-26	4296-4297	’	_	_	_	_
24-27	4298-4299	s	abstract[213]	giv[213]	coref	27-1[245_213]
24-28	4300-4308	findings	abstract[213]	giv[213]	_	_
24-29	4309-4310	.	_	_	_	_

#Text=Spain ’s climate varies across its geography , resulting in three broad regions : the North , where Atlantic weather characterized by a large proportion of humid days and the prevalence of precipitation ; the Center , distinguished by a continental plateau with less precipitation ; and the South , which is characterized by a Mediterranean climate with almost no precipitation , higher temperatures , and longer , sunny days .
25-1	4311-4316	Spain	place[214]|abstract[215]	giv[214]|new[215]	ana|coref|ana|coref	25-6[0_214]|25-55[230_215]|25-6[0_214]|25-55[230_215]
25-2	4317-4319	’s	place[214]|abstract[215]	giv[214]|new[215]	_	_
25-3	4320-4327	climate	abstract[215]	new[215]	_	_
25-4	4328-4334	varies	_	_	_	_
25-5	4335-4341	across	_	_	_	_
25-6	4342-4345	its	place|abstract[217]	giv|new[217]	coref|coref	26-28|26-28
25-7	4346-4355	geography	abstract[217]	new[217]	_	_
25-8	4356-4357	,	_	_	_	_
25-9	4358-4367	resulting	_	_	_	_
25-10	4368-4370	in	_	_	_	_
25-11	4371-4376	three	place[218]	new[218]	coref	26-25[243_218]
25-12	4377-4382	broad	place[218]	new[218]	_	_
25-13	4383-4390	regions	place[218]	new[218]	_	_
25-14	4391-4392	:	_	_	_	_
25-15	4393-4396	the	place[219]	giv[219]	coref	26-7[0_219]
25-16	4397-4402	North	place[219]	giv[219]	_	_
25-17	4403-4404	,	_	_	_	_
25-18	4405-4410	where	_	_	_	_
25-19	4411-4419	Atlantic	abstract[220]	new[220]	coref	30-11[0_220]
25-20	4420-4427	weather	abstract[220]	new[220]	_	_
25-21	4428-4441	characterized	_	_	_	_
25-22	4442-4444	by	_	_	_	_
25-23	4445-4446	a	quantity[221]	new[221]	_	_
25-24	4447-4452	large	quantity[221]	new[221]	_	_
25-25	4453-4463	proportion	quantity[221]	new[221]	_	_
25-26	4464-4466	of	quantity[221]	new[221]	_	_
25-27	4467-4472	humid	quantity[221]|time[222]	new[221]|new[222]	_	_
25-28	4473-4477	days	quantity[221]|time[222]	new[221]|new[222]	_	_
25-29	4478-4481	and	_	_	_	_
25-30	4482-4485	the	abstract[223]	new[223]	_	_
25-31	4486-4496	prevalence	abstract[223]	new[223]	_	_
25-32	4497-4499	of	abstract[223]	new[223]	_	_
25-33	4500-4513	precipitation	abstract[223]|substance	new[223]|new	coref	25-44[228_0]
25-34	4514-4515	;	_	_	_	_
25-35	4516-4519	the	place[225]|place[226]	new[225]|new[226]	coref|coref|coref|coref	26-22[240_225]|26-22[241_226]|26-22[240_225]|26-22[241_226]
25-36	4520-4526	Center	place[225]|place[226]	new[225]|new[226]	_	_
25-37	4527-4528	,	place[226]	new[226]	_	_
25-38	4529-4542	distinguished	place[226]	new[226]	_	_
25-39	4543-4545	by	place[226]	new[226]	_	_
25-40	4546-4547	a	place[226]|place[227]	new[226]|new[227]	_	_
25-41	4548-4559	continental	place[226]|place[227]	new[226]|new[227]	_	_
25-42	4560-4567	plateau	place[226]|place[227]	new[226]|new[227]	_	_
25-43	4568-4572	with	place[226]|place[227]	new[226]|new[227]	_	_
25-44	4573-4577	less	place[226]|place[227]|substance[228]	new[226]|new[227]|giv[228]	coref	25-59[231_228]
25-45	4578-4591	precipitation	place[226]|place[227]|substance[228]	new[226]|new[227]|giv[228]	_	_
25-46	4592-4593	;	place[226]	new[226]	_	_
25-47	4594-4597	and	place[226]	new[226]	_	_
25-48	4598-4601	the	place[226]|place[229]	new[226]|new[229]	coref	26-25[0_229]
25-49	4602-4607	South	place[226]|place[229]	new[226]|new[229]	_	_
25-50	4608-4609	,	_	_	_	_
25-51	4610-4615	which	_	_	_	_
25-52	4616-4618	is	_	_	_	_
25-53	4619-4632	characterized	_	_	_	_
25-54	4633-4635	by	_	_	_	_
25-55	4636-4637	a	abstract[230]	giv[230]	_	_
25-56	4638-4651	Mediterranean	abstract[230]	giv[230]	_	_
25-57	4652-4659	climate	abstract[230]	giv[230]	_	_
25-58	4660-4664	with	abstract[230]	giv[230]	_	_
25-59	4665-4671	almost	abstract[230]|substance[231]	giv[230]|giv[231]	_	_
25-60	4672-4674	no	abstract[230]|substance[231]	giv[230]|giv[231]	_	_
25-61	4675-4688	precipitation	abstract[230]|substance[231]	giv[230]|giv[231]	_	_
25-62	4689-4690	,	abstract[230]	giv[230]	_	_
25-63	4691-4697	higher	abstract[230]|abstract[232]	giv[230]|new[232]	_	_
25-64	4698-4710	temperatures	abstract[230]|abstract[232]	giv[230]|new[232]	_	_
25-65	4711-4712	,	abstract[230]	giv[230]	_	_
25-66	4713-4716	and	abstract[230]	giv[230]	_	_
25-67	4717-4723	longer	abstract[230]	giv[230]	_	_
25-68	4724-4725	,	abstract[230]	giv[230]	_	_
25-69	4726-4731	sunny	abstract[230]|time[233]	giv[230]|new[233]	_	_
25-70	4732-4736	days	abstract[230]|time[233]	giv[230]|new[233]	_	_
25-71	4737-4738	.	_	_	_	_

#Text=The higher IE incidence in the North region may be due to the higher level of humidity experienced there compared to the Center or South regions of Spain .
26-1	4739-4742	The	abstract[235]	giv[235]	_	_
26-2	4743-4749	higher	abstract[235]	giv[235]	_	_
26-3	4750-4752	IE	object|abstract[235]	giv|giv[235]	coref	28-18
26-4	4753-4762	incidence	abstract[235]	giv[235]	_	_
26-5	4763-4765	in	abstract[235]	giv[235]	_	_
26-6	4766-4769	the	abstract[235]|place[237]	giv[235]|new[237]	_	_
26-7	4770-4775	North	abstract[235]|place|place[237]	giv[235]|giv|new[237]	_	_
26-8	4776-4782	region	abstract[235]|place[237]	giv[235]|new[237]	_	_
26-9	4783-4786	may	_	_	_	_
26-10	4787-4789	be	_	_	_	_
26-11	4790-4793	due	_	_	_	_
26-12	4794-4796	to	_	_	_	_
26-13	4797-4800	the	abstract[238]	new[238]	_	_
26-14	4801-4807	higher	abstract[238]	new[238]	_	_
26-15	4808-4813	level	abstract[238]	new[238]	_	_
26-16	4814-4816	of	abstract[238]	new[238]	_	_
26-17	4817-4825	humidity	abstract[238]|substance	new[238]|new	coref	29-14[260_0]
26-18	4826-4837	experienced	_	_	_	_
26-19	4838-4843	there	_	_	_	_
26-20	4844-4852	compared	_	_	_	_
26-21	4853-4855	to	_	_	_	_
26-22	4856-4859	the	place[240]|place[241]	giv[240]|giv[241]	_	_
26-23	4860-4866	Center	place[240]|place[241]	giv[240]|giv[241]	_	_
26-24	4867-4869	or	place[241]	giv[241]	_	_
26-25	4870-4875	South	place[241]|place|place[243]	giv[241]|giv|giv[243]	_	_
26-26	4876-4883	regions	place[241]|place[243]	giv[241]|giv[243]	_	_
26-27	4884-4886	of	place[241]|place[243]	giv[241]|giv[243]	_	_
26-28	4887-4892	Spain	place[241]|place[243]|place	giv[241]|giv[243]|giv	_	_
26-29	4893-4894	.	_	_	_	_

#Text=These findings emphasized the importance of the site of acquisition .
27-1	4895-4900	These	abstract[245]	giv[245]	coref	29-4[259_245]
27-2	4901-4909	findings	abstract[245]	giv[245]	_	_
27-3	4910-4920	emphasized	_	_	_	_
27-4	4921-4924	the	abstract[246]	new[246]	ana	28-7[0_246]
27-5	4925-4935	importance	abstract[246]	new[246]	_	_
27-6	4936-4938	of	abstract[246]	new[246]	_	_
27-7	4939-4942	the	abstract[246]|place[247]	new[246]|new[247]	_	_
27-8	4943-4947	site	abstract[246]|place[247]	new[246]|new[247]	_	_
27-9	4948-4950	of	abstract[246]|place[247]	new[246]|new[247]	_	_
27-10	4951-4962	acquisition	abstract[246]|place[247]|event	new[246]|new[247]|new	_	_
27-11	4963-4964	.	_	_	_	_

#Text=Indeed , to our knowledge , this is the first study to report a significant difference in IE rates in terms of location .
28-1	4965-4971	Indeed	_	_	_	_
28-2	4972-4973	,	_	_	_	_
28-3	4974-4976	to	_	_	_	_
28-4	4977-4980	our	person|abstract[250]	giv|new[250]	_	_
28-5	4981-4990	knowledge	abstract[250]	new[250]	_	_
28-6	4991-4992	,	_	_	_	_
28-7	4993-4997	this	abstract	giv	coref	28-9[252_0]
28-8	4998-5000	is	_	_	_	_
28-9	5001-5004	the	abstract[252]	giv[252]	_	_
28-10	5005-5010	first	abstract[252]	giv[252]	_	_
28-11	5011-5016	study	abstract[252]	giv[252]	_	_
28-12	5017-5019	to	_	_	_	_
28-13	5020-5026	report	_	_	_	_
28-14	5027-5028	a	abstract[253]	new[253]	_	_
28-15	5029-5040	significant	abstract[253]	new[253]	_	_
28-16	5041-5051	difference	abstract[253]	new[253]	_	_
28-17	5052-5054	in	abstract[253]	new[253]	_	_
28-18	5055-5057	IE	abstract[253]|object|abstract[255]	new[253]|giv|giv[255]	_	_
28-19	5058-5063	rates	abstract[253]|abstract[255]	new[253]|giv[255]	_	_
28-20	5064-5066	in	abstract[253]|abstract[255]	new[253]|giv[255]	_	_
28-21	5067-5072	terms	abstract[253]|abstract[255]	new[253]|giv[255]	_	_
28-22	5073-5075	of	abstract[253]|abstract[255]	new[253]|giv[255]	_	_
28-23	5076-5084	location	abstract[253]|abstract[255]|abstract	new[253]|giv[255]|new	ana	29-1
28-24	5085-5086	.	_	_	_	_

#Text=This corresponds with Blanco et al. ’ s findings , who demonstrated that increasing humidity is associated with greater Staphylococcus aureus colonization .
29-1	5087-5091	This	abstract	giv	_	_
29-2	5092-5103	corresponds	_	_	_	_
29-3	5104-5108	with	_	_	_	_
29-4	5109-5115	Blanco	person|abstract[259]	new|giv[259]	_	_
29-5	5116-5118	et	abstract[259]	giv[259]	_	_
29-6	5119-5122	al.	abstract[259]	giv[259]	_	_
29-7	5123-5124	’	abstract[259]	giv[259]	_	_
29-8	5125-5126	s	abstract[259]	giv[259]	_	_
29-9	5127-5135	findings	abstract[259]	giv[259]	_	_
29-10	5136-5137	,	_	_	_	_
29-11	5138-5141	who	_	_	_	_
29-12	5142-5154	demonstrated	_	_	_	_
29-13	5155-5159	that	_	_	_	_
29-14	5160-5170	increasing	substance[260]	giv[260]	coref	30-22[0_260]
29-15	5171-5179	humidity	substance[260]	giv[260]	_	_
29-16	5180-5182	is	_	_	_	_
29-17	5183-5193	associated	_	_	_	_
29-18	5194-5198	with	_	_	_	_
29-19	5199-5206	greater	abstract[262]	new[262]	_	_
29-20	5207-5221	Staphylococcus	place|abstract[262]	giv|new[262]	coref	30-24
29-21	5222-5228	aureus	abstract[262]	new[262]	_	_
29-22	5229-5241	colonization	abstract[262]	new[262]	_	_
29-23	5242-5243	.	_	_	_	_

#Text=Certainly , Staphylococcus aureus infections are more common in humid weather conditions . Wang et al. reported a similar correlation between humidity and Staphylococcus aureus infections .
30-1	5244-5253	Certainly	_	_	_	_
30-2	5254-5255	,	_	_	_	_
30-3	5256-5270	Staphylococcus	abstract[264]	giv[264]	coref	30-24[272_264]
30-4	5271-5277	aureus	object|abstract[264]	new|giv[264]	coref	30-25
30-5	5278-5288	infections	abstract[264]	giv[264]	_	_
30-6	5289-5292	are	_	_	_	_
30-7	5293-5297	more	_	_	_	_
30-8	5298-5304	common	_	_	_	_
30-9	5305-5307	in	_	_	_	_
30-10	5308-5313	humid	abstract[266]	new[266]	_	_
30-11	5314-5321	weather	abstract|abstract[266]	giv|new[266]	_	_
30-12	5322-5332	conditions	abstract[266]	new[266]	_	_
30-13	5333-5334	.	_	_	_	_
30-14	5335-5339	Wang	person	new	_	_
30-15	5340-5342	et	_	_	_	_
30-16	5343-5346	al.	_	_	_	_
30-17	5347-5355	reported	_	_	_	_
30-18	5356-5357	a	abstract[268]	new[268]	_	_
30-19	5358-5365	similar	abstract[268]	new[268]	_	_
30-20	5366-5377	correlation	abstract[268]	new[268]	_	_
30-21	5378-5385	between	abstract[268]	new[268]	_	_
30-22	5386-5394	humidity	abstract[268]|substance	new[268]|giv	_	_
30-23	5395-5398	and	abstract[268]	new[268]	_	_
30-24	5399-5413	Staphylococcus	abstract[268]|object|abstract[272]	new[268]|giv|giv[272]	_	_
30-25	5414-5420	aureus	abstract[268]|object|abstract[272]	new[268]|giv|giv[272]	_	_
30-26	5421-5431	infections	abstract[268]|abstract[272]	new[268]|giv[272]	_	_
30-27	5432-5433	.	_	_	_	_
